Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
endostar + thalidomide
- Development stage
- Unknown
- Lead developer
- CASI Pharmaceuticals
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of Endostar (recombinant human endostatin) and thalidomide. Endostar is an anti-angiogenic agent that acts on tropomyosin to inhibit endothelial cell growth at the earliest stages of angiogenesis. Thalidomide is an immunomodulatory drug with anti-angiogenic properties that modulates the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and acts as a cereblon E3 ligase modulator. Both drugs individually have shown efficacy in cancer treatment.
02
Targets
CRBN (Cereblon)
Beyond the preview
Go deeper on endostar + thalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on endostar + thalidomide.